Literature DB >> 31176584

Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria.

Carlo Giannangelo1, Freya J I Fowkes2, Julie A Simpson3, Susan A Charman4, Darren J Creek5.   

Abstract

The ozonides are one of the most advanced drug classes in the antimalarial development pipeline and were designed to improve on limitations associated with current front-line artemisinin-based therapies. Like the artemisinins, the pharmacophoric peroxide bond of ozonides is essential for activity, and it appears that these antimalarials share a similar mode of action, raising the possibility of cross-resistance. Resistance to artemisinins is associated with Plasmodium falciparum mutations that allow resistant parasites to escape short-term artemisinin-mediated damage (elimination half-life ~1 h). Importantly, some ozonides (e.g., OZ439) have a sustained in vivo drug exposure profile, providing a major pharmacokinetic advantage over the artemisinin derivatives. Here, we describe recent progress made towards understanding ozonide antimalarial activity and discuss ozonide utility within the context of artemisinin resistance.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  artemisinin resistance; artemisinins; mechanism of action; ozonide antimalarials

Mesh:

Substances:

Year:  2019        PMID: 31176584     DOI: 10.1016/j.pt.2019.05.002

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  9 in total

1.  Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii.

Authors:  Alex Rosenberg; Madeline R Luth; Elizabeth A Winzeler; Michael Behnke; L David Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

2.  Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance.

Authors:  Xinsong Li; Leann Tilley; Yawei Du; Carlo Giannangelo; Wei He; Gerald J Shami; Wenya Zhou; Tuo Yang; Darren J Creek; Con Dogovski
Journal:  Antimicrob Agents Chemother       Date:  2022-04-13       Impact factor: 5.938

3.  System-wide biochemical analysis reveals ozonide antimalarials initially act by disrupting Plasmodium falciparum haemoglobin digestion.

Authors:  Carlo Giannangelo; Ghizal Siddiqui; Amanda De Paoli; Bethany M Anderson; Laura E Edgington-Mitchell; Susan A Charman; Darren J Creek
Journal:  PLoS Pathog       Date:  2020-06-26       Impact factor: 6.823

Review 4.  Antimalarial and anticancer properties of artesunate and other artemisinins: current development.

Authors:  Pitambar Khanal
Journal:  Monatsh Chem       Date:  2021-03-30       Impact factor: 1.451

5.  Peroxide Antimalarial Drugs Target Redox Homeostasis in Plasmodium falciparum Infected Red Blood Cells.

Authors:  Ghizal Siddiqui; Carlo Giannangelo; Amanda De Paoli; Anna Katharina Schuh; Kim C Heimsch; Dovile Anderson; Timothy G Brown; Christopher A MacRaild; Jianbo Wu; Xiaofang Wang; Yuxiang Dong; Jonathan L Vennerstrom; Katja Becker; Darren J Creek
Journal:  ACS Infect Dis       Date:  2022-01-05       Impact factor: 5.084

6.  Biological Activities and the Essential Oil Analysis of Cousinia harazensis and C. calocephala.

Authors:  Ebrahim Salimi-Sabour; Farshad H Shirazi; Arash Mahboubi; Faraz Mojab; Mahboubeh Irani
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 7.  Liposomal Ozonated Oil in Ocular Infections: A Review of Preclinical and Clinical Studies, Focusing on Its Antiseptic and Regenerative Properties.

Authors:  Juan J Pérez-Santonja; José Luis Güell; Oscar Gris; Xose Manuel Vázquez Dorrego; Esther Pellicer; Jose Manuel Benítez-Del-Castillo
Journal:  Clin Ophthalmol       Date:  2022-06-14

8.  Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439.

Authors:  David M Shackleford; Francis C K Chiu; Kasiram Katneni; Scott Blundell; Jenna McLaren; Xiaofang Wang; Lin Zhou; Kamaraj Sriraghavan; André M Alker; Daniel Hunziker; Christian Scheurer; Qingjie Zhao; Yuxiang Dong; Jörg J Möhrle; Nada Abla; Hugues Matile; Sergio Wittlin; Jonathan L Vennerstrom; Susan A Charman
Journal:  ACS Infect Dis       Date:  2021-06-08       Impact factor: 5.578

9.  Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.

Authors:  Mainga Hamaluba; Rob W van der Pluijm; Joseph Weya; Patricia Njuguna; Mwanajuma Ngama; Peter Kalume; Gabriel Mwambingu; Caroline Ngetsa; Juliana Wambua; Mwanamvua Boga; Neema Mturi; Altaf A Lal; Arshad Khuroo; Walter R J Taylor; Sónia Gonçalves; Olivo Miotto; Mehul Dhorda; Brian Mutinda; Mavuto Mukaka; Naomi Waithira; Richard M Hoglund; Mallika Imwong; Joel Tarning; Nicholas P J Day; Nicholas J White; Philip Bejon; Arjen M Dondorp
Journal:  Lancet Infect Dis       Date:  2021-06-07       Impact factor: 71.421

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.